CAB >= clinical trials
CAB >= is named as an intervention in 2 current clinical trials in our USA and Brazil registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is ViiV Healthcare (1). The most-studied condition is HIV Infections.
Patient leaflets for CAB >=
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CAB >=
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
NCT05418868 · HIV Infections
|
Phase 1 | Recruiting | ViiV Healthcare | USA |
|
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
NCT05660980 · ClinicalTrials.gov ↗ · HIV-1-infection
|
Phase 1/2 | Active, closed | National Institute of Allergy and Infectious Diseases (NIAID) | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with CAB >=
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| ViiV Healthcare | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about CAB >= trials
How many clinical trials are testing CAB >=?
2 current trials in our USA and Brazil registers name CAB >= as a drug or biological intervention, as of the registry sync on 6 November 2026. Completed and withdrawn studies are not counted.
Are CAB >= trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CAB >= clinical trials?
ViiV Healthcare (1) and National Institute of Allergy and Infectious Diseases (NIAID) (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CAB >= works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CAB >= works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CAB >= (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 6 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.